Protagonist Therapeutics (PTGX) Common Equity (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Common Equity data on file, last reported at $655.5 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 4.87% year-over-year to $655.5 million; the trailing twelve-month figure through Mar 2026 stood at $655.5 million (down 4.87% YoY), and the FY2025 full-year result was $614.7 million, down 8.97% from the prior year.
• Common Equity rose to $655.5 million in Q1 2026, from $614.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $689.1 million in Q1 2025 to a low of $215.6 million in Q4 2022.
• A 5-year average of $456.5 million and a median of $531.9 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity retreated 28.37% in 2023 and soared 159.26% in 2024, its largest moves.
• Tracing PTGX's Common Equity over 5 years: stood at $215.6 million in 2022, then surged by 56.15% to $336.7 million in 2023, then soared by 100.58% to $675.3 million in 2024, then slipped by 8.97% to $614.7 million in 2025, then advanced by 6.63% to $655.5 million in 2026.
• Business Quant data shows PTGX's Common Equity at $655.5 million in Q1 2026, $614.7 million in Q4 2025, and $645.4 million in Q3 2025.